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PENGGUNAAN PENYARINGAN ASAI BERASASKAN SEL
UNTUK PENCARIAN CALON ANTI DIABETIS JENIS II DARI PRODUK
SEMULAJADI MALAYSIA DENGAN MENGGUNAKAN
LIGAN PPAR- γ SEBAGAI MODEL
ABSTRAK
Pengaktif PPARγ sering digunakan dalam terapi penyakit diabetis jenis 2 dan
pembangunan ubat diabetis. Hal ini disebabkan , PPARγ telah terbukti menunjukkan
kebolehannya dalam meningkatkan sensitivti insulin di dalam sel. Sejak zaman dulu,
tumbuhan ubatan telah banyak digunakan untuk merawat diabetis dan penyelidikan
terkini telah membuktikan keberkesanan persediaan herba-herba ini. Dalam kajian
ini, potensi 300 ekstrak sumber semulajadi Malaysia ke atas aktiviti anti diabetis
telah diuji melalui penyaringan transktivasi PPARγ menggunakan sel hati (HepG2)
sebagai model dan aktivitinya dinilai melalui keamatan luminisen yang dihasilkan
oleh unsur tindakbalas pengaktif peroksisom (PPRE). Kesan anti-diabetis jenis 2
telah diuiji menggunakan asai pematangan sel lemak memandangkan kebanyakan
PPARγ semulajadi hadir di dalam sel lemak. Dalam asai ini, kesan pengaktifan
PPARγ ekstrak telah dinilai melalui keupayaannya untuk mematangkan sel pra-
lemak tikus (3T3-L1) menjadi sel lemak. Ekstrak daripada pokok aktif yang dikenali
sebagai Rourea mimosoides merencat kematangan sel lemak, meningkatkan
keupayaan pengambilan glukosa dalam sel C2C12 dan meningkatkan ekspresi gen
PPARγ sebanyak 6.84 kali ganda pada kepekatan 0.625g/ml berbanding dengan
rosiglitazone (10M) yang menunjukkan peningkatan ekspresi gen PPARγ sebanyak
6 kali ganda sahaja. Kajian fitokimia telah membawa kepada pengasingan bahan
xviii
aktif yang dikenali sebagai Benzene dicarboxylic acid, diisooctyl ester (sebatian 1)
yang berkeupayaan untuk mempertingkatkan transaktiviti PPARγ sebanyak 17.91±
0.65 kali ganda pada kepekatan 1.56nM. Tambahan pula, kesan toksisiti sebatian 1
telah dikaji terhadap sel HepG2, C2C12 dan 3T3-L1 menggunakan asai Alamar biru
dan keputusan yang diperolehi menunjukkan yang sebatian 1 adalah tidak toksi
kepada sel-sel tersebut. Oleh itu, penemuan kajian ini menunjukkan bahawa PPARγ
adalah merupakan molekul sasaran untuk ekstrak R. mimosoides dan sebatian aktif 1
yang boleh memberi kefahaman tentang potensi kesan anti-diabetis jenis 2 pokok R.
Mimosoides.
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APPLICATION OF CELL-BASED SCREENING FOR THE DISCOVERY OF
POTENTIAL ANTI TYPE II DIABETES CANDIDATE FROMMALAYSIAN
NATURAL PRODUCT USING PPARγ LIGAND AS MODEL
ABSTRACT
Peroxisome proliferator –activated receptor (PPAR)-γ activators are commonly used
in type 2 diabetes therapy or even drug research as they improved the sensitivity of
insulin receptors in cell. Since ancient, medicinal plants have been used to treat
diabetes mellitus and recent research proved the efficacy of these preparations and
some of which are remarkably effective . In this study, anti-type 2 diabetes properties
of the methanol extract of a total of 300 Malaysian natural products were subjected
to PPARγ transactivation activity assay using liver hepatocellular carcinoma (HepG2)
cell as model and the activity was assessed through the intensity of the luminescence
produced by peroxisome proliferator response element (PPRE) . The anti type 2
diabetes mellitus properties was also tested using adipocyte differentiation assay as
most of the naturally accuring PPARγ is present in adipose cell. In the assay, the
PPARγ activation properties of the extracts were assessed through its ability to
differentiate the mouse pre-adipocyte (3T3-L1) cell into adipose cell. Extract from
active plant identified as Rourea mimosoides was shown to inhibit adipocyte
differentiation, increased the ability to enhance glucose uptake in C2C12 myoblast
cells and increased the PPARγ gene expression by 6.84 fold at the concentration of
0.625g/ml as compared to rosiglitazone (10which showed 6 fold increase of
the PPARγ gene expression. Phytochemical investigation has led to the isolation of
the active compound identified as benzenedicarboxylic acid, diisooctyl ester
xx
(compound 1) which was found to increase the PPARγ transactivation by 17.91±
0.65 fold at the concentration of 1.56nM. Furthermore, the toxicity of compound 1
was investigated on HepG2, C2C12 myoblast and 3T3-L1 cells through Alamar blue
assay and the results suggested that the compound was not toxic to the cells. Thus,
the findings indicated that PPARγ is a molecule target of Rourea mimosoides extract
and active compound 1 that may provide a better understanding of the potential of
anti-diabetes type 2 properties of R. mimosoides.
1CHAPTER 1
INTRODUCTION
1.1 Diabetes Mellitus
Metabolism is a process where ingested food is broken-down into glucose and
utilized for energy generation and cell growth purposes. Glucose is then transported
to the body parts via blood stream. However, glucose is unable to enter cells or
tissues in the absence of insulin, a type of hormone which facilitates the diffusion of
glucose from blood stream into cell or tissue. Deficiency of insulin action will cause
glucose to remain in the blood and over time, the level of blood glucose will increase
causing diabetes mellitus (DM) or diabetes (Kuzuya et al., 2002); a metabolic disease
resulting from chronic hyperglycemia. A Greek physician used this term to describe
a patient having high blood glucose, passing too much water or polyuria, and feeling
thirsty all the time or polydipsia. DM may be caused by several factors depending
on its type, but in general DM may be caused by a sedentary life style (for example:
low exercise level, cigarette smoking, high glucose intake, alcohol consumption,
obesity and etc.) (Ripsin et al., 2009), genetic factors (for example: defect of β cell
function, mutation of insulin receptor and hereditary) and environmental toxin
(Roder et al., 2000).
In 1980, Expert Committee on Diabetes Mellitus of WHO was classified
diabetes mellitus into Type 1 Diabetes, Type 2 Diabetes, Malnutrition-Related
Diabetes Mellitus (MRDM), and Gestational Diabetes Mellitus (GDM) according to
the insulin deficiency degreed by WHO in 1985. While in year 1999, it was reported
by WHO, diabetes mellitus is tended to be classified according to the causes of the
disease rather than by the insulin defiency level. The terms Insulin Dependent
2Diabetes Mellitus (IDDM) and Non-insulin Dependent Diabetes Mellitus (NIDDM)
are used to describe the stages of diabetes and the various degree of insulin
deficiency (World Health Organization). According to WHO diabetes mellitus type 1
or IDDM is refer to the diabetes which caused by the failure of insulin secretion in
betal cell and eventually the patient diagnosed with diabetes mellitus type will
needed insulin injection to control their blood glucose level. While diabetes mellitus
which caused by the low sensitivity of insulin or insulin resistance is classified as
diabetes mellitus type 2 (Kuzuya et al., 2002). Like other clinical classes’ diseases,
diabetes mellitus can be divided into non-diabetic, pre-diabetes, diabetic with no
insulin therapy required and diabetic with insulin therapy required. At the last stage,
insulin therapy is required to reduce the blood glucose level for survival purposes
(ADA, 1997 & WHO, 1999). Clinically, history of disease, glycemic level, plasma
insulin and C-peptide assay in urine are required in the evaluation of the insulin
deficiency degree, and tend to be used to detect the stages of diabetes (Chikazawa et
al., 1985).
Symptom is a departure from normal functioning which is noticeable by
patient and thus symptoms may indicate diseases or abnormalities being present.
Diabetes mellitus can be suspected with the presence of some particular symptoms
such as: being constantly tired, unexplained weight loss, polyuria, polyphagia,
polydipsia, poor wound healing ability, and unclear vision (Cooke & Plotnick, 2008;
Robert, 2011). However not all symptoms will appear in a diabetes patient. The most
common ones are polyuria, where a patient suffers from excessive urination (Cooke
& Plotnick, 2008). This may be caused by the excretion of excessive glucose in the
bloodstream into urine, and lead to dehydration (where large volumes of water are
also needed to transport glucose out from the body) (Robert, 2011). Other than
3polyuria, polydipsia is one of the most common symptoms appearing in diabetes
mellitus patient. Diabetes mellitus patient may have increased thirsty (Porth, 1990;
Cooke & Plotnick, 2008; Robert, 2011) all the time, and they may increase the
volume of water consumed to dilute the concentrated glucose in their blood (Robert,
2011). This action was stimulated by human homeostasis which encourages the body
to take in more water to dilute the glucose concentrated blood and bring the blood
glucose level back to normal level. Usually polydipsia or excessive thirst, is the
initial symptom for DM (Porth, 1990). Figure 1.1 shows illustration about the
diabetes’ symptoms.
Constantly being tired might also be one of the more common symptoms
shown in diabetes patients. Due to the deficiency of insulin in the body, glucose fails
to diffuse into cells and thus, the cell tend to uses up lipid and fats as fuel sources. In
this case, more energy is required to breakdown the components and thus the body
might feel tired easily (Robert, 2011). Another common symptom is weak wound
healing; this happens due to the white blood functioning abnormally in the
prevention of bacterial infection and dead cell digestion. High glucose levels in the
blood may affect the function of the white blood cells, thus the wound site may be
infected by bacteria or viruses frequently as the wound site needs a longer time to
heal (Robert, 2011).
A prolonged, untreated diabetes mellitus may lead to death or mortality
(Stamler et al., 1993 & Ko et al., 2000). According to the statistic by World Life
Expectancy, the mortality rate for diabetes was categorized into four levels which are
high mortality, middle high, middle, and low mortality rate. Mauritius, Guyana,
Mexico and Jordan were categorized as high diabetes mortality rate countries as a
4result of their mortality rate which was more than 61, out of 100, 000 patients . The
mortality rate of diabetes mellitus in Mauritius was the highest where out of every
100,000 patients, 176 will die from diabetes. In Malaysia, the mortality rate of
diabetes mellitus is still at the low level, where out of every 100,000 patients only 19
will die from diabetes mellitus (Wild et al., 2004). However, researchers should not
ignore the seriousness of diabetes mellitus in Malaysia, as diabetes is a life
threatening disease and in these few years, the diabetic incidence is shifting to the
young generation.
According to the study of Detournay et al., (1999) and Charpentier et al.,
(2003) diabetes mellitus might be the risk factor which leads to cardiovascular
disease, stroke, and peripheral vascular disease. Besides, diabetes mellitus may also
damage human body and small blood vessel where it will lead to two diseases which
are diabetic nephropathy, which affects the blood vessel in the kidney and the
function of the kidney and diabetic retinopathy, which affects the blood vessel in the
eyes and retina and thus may cause the blurring of vision (Boussageon et al., 2011).
The summary of the complication caused by diabetes mellitus is also shown in
Figure 1.2 Therefore, a lot of effort had been done by the researchers and also
medical practitioners, through the use of special diets in diabetes mellitus patients,
such as control of glucose intake and levels in the body (Danne et al., 2005 & Kemp
et al., 2005), oral medication, and insulin injection (Rys et al., 2011) to treat or
prevent diabetes mellitus from affecting the world’s population especially in the
younger generation.
5Figure 1.1: Symptoms of Diabetes mellitus (Disease and cures, health tips. Retrieved
on 7th October 2015)[ ebloghealth.com ]
Figure 1.2: Vascular complication caused by Diabetes mellitus (Disease and cures,
health tips. Retrieved on 7th October 2015)[tabletsmanual.com]
61.1.1 Diabetes Mellitus Type 1
Diabetes Mellitus type 1(T1D) or Insulin-Dependent Diabetes Mellitus (or
commonly called juvenile diabetes) is a catabolic disorder where the autoimmune
destruction of β-cell in the pancreas has happened and leads to insulin production
deficiency (Kuzuya et al., 2002). Insulin deficiency in a patient of T1D actually is
affected by the dysfunction of β-cell or Islet of Langerhans (caused by infection of
virus or environmental toxin) and the infiltration of lympohotic in the pancreas
(Khardori et al., 2011). According to the study of Yoon et al., (1989) and Dotta et al.,
(2007), viruses are one of the factors which caused the dysfunction of the β-cell and
lead to T1D (Figure 1.3). The Encephalomyocarditis (EMC) virus, Coxsackie B4
virus, Mengo virus 2T, Rubella, Mumps, Epstein-Barr virus, Varicella zoster virus
are those detected viruses that infect the Islet of Langerhans cell (Ginsberg-Fellner et
al., 1984; Chikazawa et al., 1985; Surcel et al., 1987; Hyoty et al., 1988; Yoon et al.,
1989; Jali & Shankar, 1990). Infection of these viruses may cause the pancreatic β-
cell to be auto-immune. The body’s immune system may produce anti- insulin
antibodies to attack the insulin produced by pancreas (Khardori et al., 2011). Thus
the deficiency of insulin production may lead to ketosis, hyperglycemia and
abnormal lipid and protein metabolis.
The credibility of the virus infection leading to diabetes type 1 still was an
issue among scientists. King et al., (1983) proved that Coxsackie B4 viruses had
been detected from the children who were diagnosed with diabetes type 1, this
finding was then further supported by the study of Banatvala et al., (1985). However
this finding had been overthrown through the study of Yoon et al., (1986), in their
study, they found that not all monkeys had high glucose levels or developed
7abnormalities in insulin secretion when injected with Coxsackie B4 virus. Thus,
Yoon and the research team concluded that Coxsackie B4 viruses may cause glucose
intolerance in certain condition. Even though some papers discredited the idea of
viral infections leading to auto-immune β-cells and diabetes type 1, there are still
some studies which stated that viral infections are associated with autoimmunity in
diabetes. Rayfield et al., (1986) and Suenaga and Yoon, (1988) reported that rubella
viruses and retroviruses are factors which caused the autoimmunity in non-obese
diabetic mouse. The effect from the autoimmunity in two types of mice causes the
increase in blood glucose level. Moreover, the rubella virus caused hypoinsulinemia
and mononuclear cell filtrate of the islet in Syrian hamster (Rayfield et al., 1986).
However, the mechanism of rubella viruses in diabetes induction still remains
unclear.
81.1.2 Diabetes Mellitus Type 2
Non-insulin dependent diabetes mellitus (NIDDM) or type 2 Diabetes Mellitus(T2D)
represents a major global public issue since 2007. The disease is a more
heterogeneous disease, in which both insulin secretion and insulin sensitivity are
impaired and usually diagnosed in adults above the age of 40. Currently this disease
is affecting more than 100 million people in the world (Wild et al., 2004). Through
the expression of the diabetic patient number, the incidence was projected to increase
up to 300 million people in year 2030. According to the WHO report year 2010, the
diabetes type 2 incidence in Malaysia was predicted to be raised from 3.48% to
6.38% in 2030. To date diabetes type 2 remains a serious metabolic disorder, despite
the numerous preventative strategies and medications. Diabetes type 2 might lead to
chronic damages to body systems if the disease is not properly managed in the long
term.
Diabetes type 2 is caused by the complex interactions of many factors. The
two major factors that cause diabetes type 2 are insufficient insulin secretion in the
pancreas and impaired glucose uptake in the muscles, liver and adipose cell, which is
caused by the resistance of the action of insulin (Cheng & George Fantus , 2005).
Insulin plays an essential role in glucose homeostasis, in order to regulate the
cascade of fatty acid and glucose uptake through a series of protein mechanisms
(Koopmans et al., 1999). During the glucose homeostasis, adipose and muscle cells
are stimulated by insulin to uptake the blood glucose and further breakdown into
pyruvate or glycogen, and stored in the muscles and liver cells (Bergam, 1997).
However, in the case of diabetes type 2, adipose and muscle cells are not sensitive to
the action of insulin, thus the cells are unable to uptake the glucose. Hence, it causes
9a high level of glucose being detected in the blood, which is called hyperglycemia
(Krssak & Roden, 2004).
Moreover, excessive free amino acids or fat, may cause an impairment of
glucose uptake. Diabetes type 2 patients are highly associated with obesity, which
increases the risk of insulin resistance and blood glucose elevation. A high level of
fatty acids in the bloodstream will stimulate the secretion of cytokines in the adipose
cell and subsequently increase the insulin resistance. In addition, free fatty acids
cause the damages of beta cell in pancreas. Thus, the pancreatic insulin production
and secretion will be affected, which leads to the impairment of glucose uptake,
causing high glucose levels in the bloodstream (Cheng & George Fantus, 2005). As
reported in Centre of Diseases Control (CDC) national fact sheet in year 2011,
diabetes type 2 was diagnosed also in youngsters instead of adult; this is due to the
increase in the levels of obesity among children and youngster in recent year.
According to the report, most of the diabetes type 2 young patient possesses family
histories of type 2 diabetes as well as insulin resistance.
1.2 PPARs family
Peroxisome proliferator-activated receptors (PPARs) are one of the transcriptional
factors in the nuclear receptors superfamily, which regulate gene expression through
ligand activation (Desvergne & Wahli , 1999; Ogata et al., 2002). PPARs can be
activated either by natural ligand, such as fatty acids, steroid hormones, thyroid
hormones and vitamin D, or synthetic compound such as thiazolidinediones (TZD)
class drug, troglitazones and rosiglitazones (Ogata et al., 2002; Katherine et al.,
2009). In addition to this, PPARs form a heterodimer with the Retinoid X Receptor
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(RxR) prior to binding with the Peroxisome Proliferator Response Element (PPRE)
to regulate gene expression which not only controls lipid metabolism, glucose
homeostasis and inflammation, but also embryo implantation (Schoonjans et al.,
1996; Fajas et al., 1997; Desvergne & Wahli, 1999; Ogata et al., 2002). Besides,
PPARs has also been implicated in many biological-related diseases treatments and
drug development such as hypolipidaemia agent, anti-inflammatory agent, anti-
cancer agent and oral anti-diabetes agent.
There are 3 distinct PPAR subtypes namely, PPAR-Alpha (PPARα), PPAR –
beta (PPARβ) and PPAR-gamma (PPAR). Each subtype is encoded by separate
genes with specific tissue distribution pattern (Dreyer et al., 1992; Kliewer et al.,
1994; Pineda et al., 2002). PPARα is highly expressed in those tissues rich with
mitochondria such as the liver, heart and muscle tissue. While PPAR-β is found in
most body tissues but rarely found in adipose tissue. PPAR is mainly found in
adipose tissue. Each subtype has its own specific functions, for example PPARα
regulate the gene expression in lipoprotein metabolism and PPAR is mainly
involved in glucose homeostasis (Sugii et al., 2009). Based on the research report,
PPAR is also the molecule target for TZD which is an anti type 2 diabetic drug
(Chawla et al., 2001; Chinetti et al., 2001; Park et al., 2001; Boitier et al., 2003).
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1.3 Peroxisome Proliferator-activated Receptor (PPAR)
PPAR is one of the members belonging to nuclear hormone receptor (NHR)
superfamily, which functions as ligand-activated transcription factors. The first
discovery of PPAR was in 1992 by Dreyer and the research team through the
homology cloning in the Xenopus frog’s liver. PPAR was discovered as a potent
therapy target for various metabolic syndromes such as obesity, diabetes etc (Zaman
et al., 2000; Marx et al., 2002). There are two isoforms of PPAR, including PPAR-
1 and PPAR-2, which are distributed at different part of body tissues. PPAR-2
contains an additional 30 amino acids at the N-terminal and is mostly found in
adipose tissues which play an essential role in adipocyte differentiation, lipid and
glucose homeostasis. PPAR-1 is found in most of the body tissue (liver, skeletal
muscle, breast, colon and the immune system) (Greene et al., 1995; Vidal-Puig et al.,
1996; Spiegleman, 1997; Desvergne and Wahli, 1999; Fajas et al., 1999; Maeda et al.,
2001).
Like other PPARs members, PPAR functions as transcriptional factors
through the formation of the heterodimer complex with RXRα. This complex is
further bound to specific DNA response elements which are called Peroxisome
proliferator response element (PPRE) at domain E/F to regulate the upstream action
(Kliewer et al., 1992; Mangelsdorf and Evans, 1995). According to the study of
Nakshatri and Chambon (1994), PPAR-RXR binds directly at the sequences of –
AGGTCA- situated with the DR1 elements. As reported, the binding of
PPAR/RXRα heterodimer will cause the interactions between PPAR and upstream
extended core hexamer of DR1 to occur (Jpenberg et al., 1997). Hence, recognition
of DR1 in PPRE is important for the docking purposes of PPAR/RXRα .
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Figure 1.3: Structure domains of human PPARs (Techibana et al., 2008)
PPAR is built up with four distinct function domains which included A/B, C, D, E/F
(Figure 1.3). N-terminal A/B domain with ligand independent activation function
1(AF-1) is responsible for phosphorylation, DNA binding domain (DBD), hinge
region for cofactors docking, and C-terminal ligand-binding domain (LBD) with
activation function 2 (AF-2) to promote the recruitment of cofactors required for
gene transcription respectively. The number inside each domain corresponds to the
percentage of amino acid sequence identity of human PPAR and PPARβ relative to
PPARα (Ranjan, 2002; Techibana et al., 2008)
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1.4 Mode of action of PPAR
The mechanism of actions of the PPARs members had been studied in the past
twenty years. However, the mode of action of PPAR had been widely studied
compared to the other PPARs isoforms (PPARα and PPARβ/). Recently, scientists
reported that PPAR not only plays an important role in cellular homeostasis and is
highly related to metabolic diseases; it also acts as the target of anti-diabetic drug in
T2D therapy (Issesmann and Green, 1990). The mechanism of actions of PPARhad
been reported as being similar to PPARα and PPARβ/. Principally, four distinct
functional domains which included domain A/B, C, D and E/F had been identified in
PPAR protein (Desvergne and Wahli, 1999). As reported, N-terminal domain or
A/B domians which consists of ligand independent activation function 1(AF-1) is
responsible for phosphorylation at DNA binding domain (DBD) (Figure 1.4). To
promote the binding of PPAR to PPRE, two zinc fingers in C domain will recognize
the specific DNA response region and hold the PPAR and PPRE in the promoter
region of targeted genes (Kliewer et al., 1992; Werman et al., 1997). As discussed in
previous topic, PPAR function through the ligand –activation; thus, to trigger the
upstream regulation of PPAR prior binding to PPRE, E/F domain or ligand binding
domain (LBD) exhibits a strong ligand dependent activation function (AF-2) which
only allow a specific ligand to bind with the receptor to trigger the activation of the
PPARbinding process (Ranjan, 2002; Techibana et al., 2008).
.
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Figure 1.4 : Schemic view of PPAR action. After a ligand binds to PPAR, PPAR
dissociates from corepressor, recruits coactivator, heterodimerizes with 9-cis-retinoic
acid receptor (RA), and then binds to a DR1 or DR2 response element, which either
activates or represses PPAR target genes. PPAR activity is also controlled by both
protein degradation and phosphorylation (Chen et al., 2003)
PPRE: PPAR- responsive element; RXR : retinoid X receptor
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1.5 Cofactors and Ligand of PPAR
The function of PPAR is regulated by common co-factors. Co-factors for PPAR
can be separated into co-activators or co-repressors of the nuclear receptor family
(Powell et al., 2007). Examples of co-activators are steroid receptor co-activators
1(SRC-1), CREB binding protein(CBP), P160 steroid receptor co-activator family,
and TRAP220/Med 1(McInerney et al., 1998).To activate the transcription process
of PPAR, a co-activator binding site is created when there is the conformational
change in ligand binding d555omain (LBD), triggered by the binding of ligand to the
receptor. Leucine amino aci (LXXLL) motifs in each co-activator’s protein will
cause the co-activators to bind or attach with the co-activator binding groove in LBD
which triggers the docking process further. Leucine amino acid (LXXLL) motifs are
present in most of the co-activators where the L denotes leucine and X denotes any
amino acid (Heery et al., 1997; Torchia et al., 1997 and McInerney et al., 1998).
Binding of different PPAR to the nuclear receptor will trigger different
conformational changes in the LBD, thus it will induce different downstream
biological effects. With this specificity of conformational changes; recruitment of
nuclear receptors are promoted and stimulate the transcription of their targeted genes
(McKenna & O’Malley, 2002)
Most of the PPAR ligands are soluble in fat or hydrophobic ligand. Thus to
associate the binding between PPAR and ligand; intracellular lipid binding proteins
(iLBP) (member of the family of fatty acid-binding proteins, FABPs) play an
important role to act as a transportation medium to allow ligand to travel in cytosol
before the ligand diffused into the nucleus to bind with PPAR to form a heterodimer
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with RxR-α (Adida and Spener 2002). Upon the formation of PPAR - RxRα
complex; transcriptional co-activators will be promoted (Torchia et al., 1997). As
mentioned, the conformational changes in LBD will recruit the transcriptional co-
activators; these co-activators will now bind to PPRE and trigger the expression of
the targeted genes. Activation of PPAR is mainly regulated by ligand binding; either
natural ligand or a synthetic ligand.
1.6 PPAR in Adipogenesis
PPAR is found abundant in adipocytes cells and it plays a very important role in
adipogenesis and lipid metabolism in mature adipocytes (Tontonoz et al., 1994a). In
general, mature adipocyte plays a role in energy homeostasis, storing and energy
production (Spiegelman and Flier, 1996).
Adipogenesis is influenced by external signals such as combining high
concentration of cyclic AMP, dexamethasone ans insulin. Furthermore , transcription
factors such as CCAAT/enhancer-binding protein α (C/EBPα) (Tang et al, 2004),
peroxisome proliferator-activated receptor ((PPAR) γ and differentiation factor 1
(ADD-1) are act to control the adipogenesis which involved in triglyceride
metabolism during the final stage of terminal differentiation. Besides, hormone such
as insulin also play a part in adipocyte differentiation along with adipogenesis factor
which including fatty acid, prostaglandins and 15-deoxy-∆12,14- PGJ2 (15d-PGJ2).
Adipocytes usually secrete a number of proteins which perform a very specific
function. Adipokines, serine protease adipsin, leptin, adiponectin, interleukin-6(IL-6),
tumor necrosis factor-α (TNF-α), resistin, and visfatin are proteins which are secreted
by adipocytes (Cook et al., 1987; Hwang et al., 1997; Berg et al., 2002; Fain et al.,
2004; Banerjee et al., 2004 and Storka et al., 2008). Moreover their biological effect
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in metabolism was well documented. These adipocytes-secretes molecules are high
contributors to obesity-associated metabolic disorder development, as well as
cardiovascular diseases, cancers and insulin resistance (Chaldakov et al., 2003).
1.7 Types of PPAR ligands
1.7.1 Natural endogenous PPARligands
Natural endogenous PPAR ligands are made mostly of fatty acid. In 1995, fatty acid
and eicosanoids were reported and implicated as being PPAR ligands by Forman et
al. 1995. In their research, they managed to demonstrate that 15-deoxy-∆12,14-
prostaglandin J2 (15d-PGJ2) bind with PPAR in adipose cell with a moderate
binding affinity which is 2.5µM. Besides this, some long-chain unsaturated fatty
acids were also reported as PPAR activators (Desvergene & Wahli, 1999). Another
group of fatty acids which included 15-lipoxygenase-derived metabolites of linoleic
acid, 13-hydroxyoctadecadienoic (13-HODE), 9-HODE, as well as their metabolites
9-oxooctadecadienoic acid (9-oxoODE) and 13 –oxoODE have also been identified
to serve as ligands of PPARNagy et al., 1998). However, from their research, these
substances were shown to be weak PPAR agonists with a low binding affinity
(Nagy et al., 1998). Thus, to maintain a high binding affinity of these natural PPAR
agonists, fatty acid was used at high concentration (30µM and above) to ensure it is
able to stimulate the downstream physiological effect.
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1.7.2 Synthetic PPAR ligands
In the past 15 years, few synthetic PPAR ligand have been identified and one of the
most common synthetic ligand would be in the TZDs class. The three members of
the TZDs class include rosiglitazone, pioglitazone and troglitazone (Figure 1.5). A
number of researches have been carried out to assess the activities of TZDs on the
hypoglycemia effect; Fortunately, TZDs showed their ability to improve the insulin
sensitivity in cell as well as to enhance the uptake of glucose in the body and hence
to reducing the blood glucose level. Thus, in 2001,rosiglitazone and troglitazone
were approved to be used in T2D treatment (Kaplan et al., 2001 and Moller, 2001).
Discovery of TZDs and its downstream biological effect on PPAR opened a
new path for T2D drug developments and design. A series of bioactive compounds
which include GI262570, GW1929, GW7845, L796449, L764406 and SB219994
have been synthesized and developed (Murakami et al., 1998; Berger et al., 1999 and
Elbrecht et al., 1999). Trans-activation activity of each compound has been tested,
and they showed high potential in activating PPAR at extremely low concentrations.
These compounds were reported to possess similar effects as TZDs; they reduce the
blood glucose levels and triglycerides levels effectively (Desvergne and Wahli 1999
and Corton et al., 2000).
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(a) Pioglitazone
(b) Rosiglitazone
(c) Troglitazone
Figure 1.5 Molecular structure of TZDs class - (a) Pioglitazone, (b) Rosiglitazone, (c)
Troglitazone are oral anti-diabetic type 2 agent.
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1.8 Thiazolidinediones (TZDs) and its side effects
Rosiglitazone and troglitazone have been approved to be used in T2D therapy. TZDs
class drug are highly recommended to be used in T2D treatment because of its high
binding affinity toward PPAR. The binding of these drugs trigger a few body
metabolisms such as carbohydrates and lipid metabolism, as well as improve insulin
sensitivity through the reduction of the circulating free fatty acids. However TZDs,
especially rosiglitazone and pioglitazone, give several side effects to patient. The
major sides effects caused by rosiglitazone are weight gain, anemia, pulmonary
edema and congestive heart failure (Herz et al., 2003).
PPAR are found not only in liver cells and muscle cells; it is also found most
abundance in adipose cells. Thus activation of PPAR by TZDs drugs might not only
lower the plasma glucose level; it will also stimulate the differentiation of adipocyte
cells and hence lead to weight gain (Herman et al., 1997). Besides, over-doses of
TZDs will also promote the terminal differentiation of malignant breast epithelial
cells which will cause cancer. On top of that, toxic effects caused by high doses of
TZDs on animals have also been reported (Herman et al., 1997).
Although the occurrences of side-effects are quite common, TZDs is the only
synthetic PPARagonists approved in clinical anti-diabetes treatment. They actually
play the role of insulin sensitizer, which are mainly designed to improve insulin
sensitivity in body cells, in order to reduce the glucose level in the bloodstream as
well as hepatic glucose level. rosiglitazone (Avandia) and pioglitazone (Actos)
(Table 1.1) were approved respectively by the US Food and Drug
Administration(FDA). Earlier, a thiazolidinedione class drug, troglitazone which was
introduced in 1997, was eventually banned due to its chronic hepatoxicity risk
(Schoonjans and Auwerx, 2000; Mudaliar and Henry, 2001).
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Table 1.1 Other synthetic oral hypoglycemia drugs (Prabhu et al., 2005).
Drugs Administration time Possible side effects
Glibenclamide Taken with meal or 15 to 30
minutes before meal
Hypoglycemia,
Obesity
Gliclazide Taken with meal Hypoglycemia
Metformin Take during or immediately
after a meal to minimize
gastrointestinal side effects
GI disturbances
Acarbose Swallow whole with liquid
before meal or chew with the
first few mouthfuls of food
GI disturbances
Repaglinide Taken with meal Hypoglycemia
Pioglitazone Taken with meal Hypoglycemia
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1.9 Anti Diabetic Potential Plants
In the past 20 years, a number of drugs have been developed and used in diabetes
therapy. One of the most popular drugs was TZDs; however the side effects caused
by the drugs have raised community’s concern. Hence, herbs or plants were
preferred to be used to treat diabetes instead of modern medicine. Traditionally,
plants have always been used as sources of drugs (Alarcon-Aguilara et al., 1998);
various medical plants or herbs were documented for their anti diabetic therapeutic
properties, which are highly effective in lowering blood glucose level and are low
cost as well as less side effects (Rohini and Vikrant , 2011).
A phenolic compound isolated from Korean red pepper has been reported to
possess anti-diabetic properties. The mechanism of the phenolic compound from
Korean red pepper towards enhancing the glucose uptake is well documented. It was
shown that the phenolic compound found in this plant exhibited anti-diabetic
activities through the activation of AMPK and PPAR signaling pathway (Yang, et
al., 2012). In previous research, phenolic compounds such as chlorogenic acid and
berberine were reported to stimulate the glucose uptake in mammalian cells through
the enhancing of GLUT 4 and PPAR gene expression (Prabhakar & Doble, 2009).
1.9.1 Potential PPARγ Ligand from Plants
Natural active compounds which serve as PPAR natural ligand are also
found in the Punica granatum flower extract. From the research result, beneficial
effects of Punica granatum flower extract and its fractionated components as anti-
diabetics was evidenced through their biological activities (Schubert et al., 1999). In
the research, these active components were used to treat macrophage cell line and
they showed the ability to enhance PPAR mRNA and protein expressions in
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macrophage cell line. One of the compounds labeled as Compound X induced the
PPAR gene expression at a concentration of 50µg/ml. Moreover, the extracts also
show the activities in enhancing glucose uptake through the expression of GLUT-4
protein (Tom Huang, et al., 2005).
PPAR transactivation properties of monascin (yellow pigment) a secondary
metabolite derived from Monacus fermented product have also been studied (Lee et
al., 2011). Monascin was reported as PPAR agonist as it is able to induce the
expression of the PPAR gene. Monascin was also acclaimed to increase the
sensitivity of C2C12 myotubes toward insulin through protein kinases B (PKB)
pathway and inhibiting the Jun-N-terminal kinase (JNK) activation. Besides, glucose
uptake ability of monascin treated C2C12 myotubes was stimulated and also induced
the expression of GLUT-4 protein in TNF-α- induced insulin resistance cell (Lee et
al., 2011).
One of the common natural sweeteners, stevioside which is isolated from
Stevia rebaudiana, has also been used in diabetes treatment for a period of time.
Stevioside has been shown to induce the secretion of insulin in the pancreas in order
to lower blood glucose level (White et al., 1994 and Jeppesen et al., 2002). Besides,
rebaudioside, a synthetic diterpene glycoside from Stevia rebaudiana, was also
shown to possess the same properties as stevioside in type 2 diabetes therapy
(Jeppesen et al., 2003). In addition, a number of anti-diabetic potential
phytochemical constituents which included alkaloids, glycosides, galactomannan,
polysaccharides, peptidoglycans, guanidine, steroids, carbohydrates, glycopeptides,
terpenoids, amino acids and inorganic ion had been isolated from plants, fruits and
herbs (Figure 1.7) (Grover et al., 2002). Some anti-diabetic plants and the solvent
used to extract the constituents are tabulated in Table 1.2.
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Table 1.2 Plants with anti-diabetic potential and the extraction solvent used
(Grover et al., 2002)
Plants Common Name Extraction solvent Active part
Allium cepa Onion Petroleum ether
Chloroform
Flesh
Allium sativum Garlic Ethanol
Petroleum ether
Ethyl ether
Flesh
Artemisia pallens Davana Methanol Aerial
Caesalpinia
bonducella
Fever nut Aqueous alcoholic Seed
Citrullus
colocynthis
Bitter apple Aqueous extract Fruit
Hibiscus rosa-
sinesis
Shoe-flower Ethanol Whole plant
Mangifera indica Mango Aqueous Seed and fruit
Momordica
charantia
Bitter Gourd Aqueous
Acetone
Ethanol
Fruit pulp, seed
and leaves
Ocimum sanctum Holy basil Ethanol Leaves
Punica granatum Pomegranate Aqueous-Ethanolic Flower
Salacia oblonga Ponkornati Aqueous
Petroleum ether
Ethyl acetate
Root bark
